Join us on Wednesday, July 29 for the live webinar
5:00 PM – 6:00 PM ET
1 AMA PRA Category 1 Credit^TM

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.

A full library of presentation slides will also be made available for those who participate in this live webinar.

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline and Merck.

Agenda

Genetic Testing in Ovarian Cancer (OC) and Biologic Basis for the Use of PARP Inhibitors

• Frequency and clinical significance of BRCA1/2 mutations and other genomic abnormalities (eg,homologous recombination deficiency) that may predict sensitivity to a PARP inhibitor
• Guideline-recommended genetic testing algorithms for patients with newly diagnosed OC
• Similarities, differences and optimal use of available genetic testing platforms
• Incidence and potential clinical relevance of other inherited mutations (eg, RAD51C, RAD51D, BRIP1)

Integration of PARP Inhibitor Maintenance into the Management of Newly Diagnosed OC

• Key clinical and biologic factors affecting the selection of patients with newly diagnosed OC for maintenance therapy with a PARP inhibitor
• Major efficacy and safety findings from the pivotal Phase III SOLO-1 trial evaluating maintenance olaparib after first-line platinum-based chemotherapy for patients with advanced OC and a BRCA mutation
• Results of the Phase III PRIMA trial evaluating maintenance niraparib after first-line platinum-based chemotherapy for patients with advanced OC
• Design, eligibility criteria and efficacy and safety data from the Phase III PAOLA-1 trial comparing olaparib/bevacizumab to bevacizumab alone for patients with advanced OC after first-line platinum-based chemotherapy and bevacizumab
• FDA approvals of olaparib and niraparib in the front-line OC setting and the optimal integration of these agents into the current management of newly diagnosed disease

Biologic Rationale for and Available Data with PARP Inhibitors in Combination with Chemotherapeutic and Immunotherapeutic Agents in the Management of Advanced OC

• Similarities and differences between veliparib and the FDA-approved PARP inhibitors; biologic rationale for combining veliparib with chemotherapy in OC
• Key efficacy and safety data from the Phase III VELIA trial evaluating the addition of veliparib to first-line chemotherapy and as maintenance therapy for high-grade OC
• Biologic rationale for and published research data (eg, from the TOPACIO and MEDIOLA trials) with the use of a PARP inhibitor in combination with an anti-PD-1/PD-L1 antibody
• Ongoing Phase III trials evaluating PARP inhibitors with immunotherapy in OC

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer.

Learning Objectives

• Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in ovarian cancer (OC), and use the results of these assessments to guide long-term treatment planning.
• Recognize the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and appropriately integrate this agent into the current care of these individuals.
• Review available trial data contributing to the FDA approval of niraparib as maintenance therapy in the first-line setting for patients with or without BRCA mutations, and consider the implications for clinical practice.
• Evaluate the key clinical data resulting in the FDA approval of olaparib in combination with bevacizumab as front-line maintenance therapy, and discern how to incorporate this therapeutic strategy into the treatment algorithm for patients with advanced OC.
• Assess available clinical trial data with and approved indications for the use of FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC to design personalized care plans potentially incorporating these agents.
• Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.
• Develop an understanding of the rationale for, available data with and potential clinical roles of PARP inhibitors in combination with chemotherapy, immunotherapy or other targeted therapy, and counsel appropriate patients about the availability of and participation in ongoing research studies.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Mirza — Advisory Committee: Karyopharm Therapeutics, Sera Prognostics; Global Clinical Lead: ENGOT-OV16/NOVA niraparib, ENGOT-EN6/NSGO-RUBY; Institutional Financial Interests (Study Grants): AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Pfizer Inc, Tesaro, A GSK Company, Ultimovacs; Personal Financial Interests: AstraZeneca Pharmaceuticals LP, BIOCAD, Clovis Oncology, Geneos Therapeutics, Genmab, Karyopharm Therapeutics, Merck, Merck Sharp & Dohme Corp, Mersana Therapeutics, Oncology Venture, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics, Sera Prognostics, SOTIO LLC, Tesaro, A GSK Company, Zai Lab. Other: Council and Faculty, European Society of Gynaecological Oncology, Chair-Elect, European Network of Gynaecological Oncological Trials Group. Dr Moore — Advisory Committee: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Merck, Mereo BioPharma, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, Merck, PTC Therapeutics; Employment: GOG Foundation/Partners. Dr Westin — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Circulogene, Clovis Oncology, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Tesaro, A GSK Company; Contracted Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, a member of the Roche Group, Novartis, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Xenetic Biosciences.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline and Merck.